Epstein-Barr virus: Exploiting the immune system

Nature Reviews Immunology

Volumn 1, Issue 1, 2001, Pages 75-82

  Thorley Lawson, David A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; LYMPHOCYTE ANTIGEN RECEPTOR; MATRIX PROTEIN;

B LYMPHOCYTE; BIOLOGICAL MODEL; EPSTEIN BARR VIRUS; GENETICS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOGENICITY; REVIEW; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS INFECTION;

ANTIGENS, CD40; B-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; GENES, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; VIRAL MATRIX PROTEINS;

EID: 0035496101     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/35095584     Document Type: Review

References (90)

1. Chen, F. et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69, 3752-3758 (1995).
2. Tierney, R. J., Steven, N., Young, L. S. & Rickinson, A. B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68, 7374-7385 (1994).
3. Qu, L. & Rowe, D. T. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66, 3715-3724 (1992).
4. Babcock, G. J., Decker, L. L., Freeman, R. B. & Thorley-Lawson, D. A. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190, 567-576 (1999).
5. Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. EBV persistence involves strict selection of latently infected B cells. J. Immunol. 165, 2975-2981 (2000).
6. Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395-404 (1998).
7. Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71, 4882-4891 (1997).
8. Henle, W. & Henle, G. in The Epstein-Barr Virus (eds Epstein, M. A. & Achong, B. G.) 61-78 (Springer-Verlag, Berlin, 1979).
9. Khan, G., Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5, 173-179 (1996).
10. Yao, Q. Y., Rickinson, A. B. & Epstein, M. A. A reexamination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int. J. Cancer 35, 35-42 (1985).
11. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162, 1827-1835 (1999).
12. Coffey, A. J. et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nature Genet. 20, 129-135 (1998).
13. Sayos, J. et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395, 462-469 (1998).
14. Hamilton, J. K. et al. X-linked lymphoproliferative syndrome registry report. J. Pediatr. 96, 669-673 (1980).
15. Purtilo, D. T., Cassel, C. K., Yang, J. P. & Harper, R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1, 935-940 (1975).
16. Pope, J. H., Horne, M. K. & Scott, W. Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int. J. Cancer 3, 857-666 (1968).
17. Aman, P., Ehlin-Henriksson, B. & Klein, G. Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J. Exp. Med. 159, 208-220 (1984).
18. Thorley-Lawson, D. A. & Mann, K. P. Early events in Epstein-Barr virus infection provide a model for B cell activation. J. Exp. Med. 162, 45-59 (1985).
19. Rickinson, A. B. & Kieff, E. in Virology 3rd edn Vol. 2 (eds Fields, B. N., Knipe, D. M., & Howley, P. M.) 2397-2446 (Lippincott-Haven, Philadelphia, 1996).
20. Brooks, L., Yao, Q. Y., Rickinson, A. B. & Young, L. S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66, 2689-2697 (1992).
21. Babcock, J. G., Hochberg, D. & Thorley-Lawson, A. D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497-506 (2000).
22. Babcock, G. J. & Thorley-Lawson, D. A. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl Acad Sci. USA 97, 12250-12255 (2000).
23. Thorley-Lawson, D. A. & Babcock, G. J. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 65, 1433-1453 (1999).
24. Fahraeus, R. et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer 42, 329-333 (1988).
25. Yates, J. L., Warren, N. & Sugden, B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815 (1985).
26. Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411 (1998).
27. Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutivefy active receptor molecule. EMBO J. 16, 6131-6140 (1997).
28. MacLennan, I. C. Germinal centers. Annu. Rev. Immunol. 12, 117-139 (1994).
29. Liu, Y. J. et al. Mechanism of antigen-driven selection in germinal centres. Nature 342, 929-931 (1989).
30. Liu, Y. J. & Arpin, C. Germinal center development. Immunol. Rev. 156, 111-126 (1997).
31. Mosialos, G. et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389-399 (1995).
32. Inoue, J. et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp. Cell Res. 254, 14-24 (2000).
33. Baker, S. J. & Reddy, E. P. Transducers of life and death: TNF receptor superfamily and associated proteins. Oncogens 12, 1-9 (1996).
34. Banchereau, J. et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881-922 (1994).
35. Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17, 1700-1709 (1998).
36. Zimber-Strobl, U. et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 15, 7070-7078 (1996).
37. Beaufils, P., Choquet, D., Mamoun, R. Z. & Malissen, B. The (YXXL/1)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J. 12, 5105-5112 (1993).
38. Miller, C. L. et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2, 155-166 (1995).
39. Kurosaki, T. Genetic analysis of B cell antigen receptor signaling. Annu. Rev. Immunol. 17, 555-592 (1999).
40. Maruyama, M., Lam, K. P. & Rajewsky, K. Memory B-cell persistence is independent of persisting immunizing antigen. Nature 407, 636-642 (2000).
41. Lam, K. P., Kuhn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073-1083 (1997).
42. Hoagland, R. J. The transmission of infectious mononucleosis. Am. J. Med. Sci. 229, 262-272 (1955).
43. Gordadze, A. V. et al. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J. Virol. 75, 5899-5912 (2001).
44. Joseph, A. M., Babcock, G. J. & Thortey-Lawson, D. A. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol. 74, 9964-9971 (2000).
45. Ling, P. D., Hsieh, J. J., Ruf, I. K., Rawlins, D. R. & Hayward, S. D. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1. J. Virol. 68, 5375-5383 (1994).
46. Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309-314 (2000).
47. Polack, A. et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)- transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl Acad. Sci. USA 93, 10411-10416 (1996).
48. Hofelmayr, H., Strobl, L. J., Marschall, G., Bornkamm, G. W. & Zimber-Strobl, U. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J. Virol. 75, 2033-2040 (2001).
49. Uchida, J. et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286, 300-303 (1999).
50. Araujo, I. et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J. Pathol. 187, 326-330 (1999).
51. Anagnostopoulos, I., Hummel, M., Kreschel, C. & Stein, H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 85, 744-750 (1995).
52. Kurth, J. et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13, 485-495 (2000).
53. Selin, L. K., Varga, S. M., Wong, I. C. & Welsh, R. M. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J. Exp. Med. 188, 1705-1715 (1998).
54. Khanna, R., Moss, D. J. & Burrows, S. R. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170, 49-64 (1999).
55. Carbone, A., Tirelli, U., Gloghini, A., Volpe, R. & Boiocchi, M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J. Clin. Oncol. 11, 1674-1681 (1993).
56. Thomas, J. A. et al. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals. Transplantation 49, 944-953 (1990).
57. Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9-13 (1995).
58. Wang, D., Liebowitz, D. & Kieff, E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43, 831-840 (1985).
59. Staudt, L. M. The molecular and cellular origins of Hodgkin's disease. J. Exp. Med. 191, 207-212 (2000).
60. Oudejans, J. J. et al. Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV. J. Clin. Pathol. 49, 897-902 (1996).
61. Pallesen, G., Hamilton-Dutoit, S. J., Rowe, M. & Young, L. S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337, 320-322 (1991).
62. Herbst, H. et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc. Natl Acad. Sci. USA 88, 4766-4770 (1991).
63. Niedobitek, G. et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 80, 1664-1672 (1997).
64. Hammarskjold, M. L. & Simurda, M. C. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-κB activity. J. Virol. 66, 6496-6501 (1992).
65. Brandtzaeg, P., Farstad I. N. & Haraldsen, G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol. Today. 20, 267-277 (1999).
66. + peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188, 1679-1689 (1998).
67. Artavanis-Tsakonas, S., Matsuno, K. & Fortini, M. E. Notch signaling. Science 268, 225-232 (1995).
68. Sullivan, J. L. & Woda, B. A. X-linked lymphoproliferative syndrome. Immunodefic. Rev. 1, 325-347 (1989).
69. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187, 1395-1402 (1998).
70. Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1, 702-703 (1964).
71. Leder, P. in Burkitt's Lymphoma: A Human Cancer Model (eds Lenoir, G. M., O'Conor, G. T. & Olweny, C. L. M.) 341-371 (Oxford Univ. Press, New York, 1985).
72. Manolov, G. & Manolova, Y. Marker band in one chromosome 14 from Burkitt lymphomas. Nature 237, 33-34 (1972).
73. Gregory, C. D., Rowe, M. & Rickinson, A. B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71, 1481-1495 (1990).
74. Muir, C. S. Cancer of the head and neck. Nasopharyngeal cancer. Epidemiology and etiology. J. Am. Med. Assoc. 220, 393-394 (1972).
75. Andersson-Anvret, M., Forsby, N., Klein, G. & Henle, W. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int. J. Cancer 20, 486-494 (1977).
76. Yu, M. C., Huang, T. B. & Henderson, B. E. Diet and nasopharyngeal carcinoma: a case-control study in Guangzhou, China. Int. J. Cancer 43, 1077-1082 (1989).
77. Klein, G. in The Epstein-Barr virus (eds Epstein, M. A. & Achong, B. G.) 340-350 (Springer-Verlag, Berlin, 1979).
78. Niedobitek, G. The Epstein-Barr virus: a group 1 carcinogen? Virchows Arch. 435, 79-86 (1999).
79. Thorley-Lawson, D. A. in Samter's Immunologic Diseases 6th edn (eds Austen, K. F., Frank, M. M., Atkinson, J. P. & Cantor, H.) 970-985 (Williams and Wilkins, New York, 2001).
80. Kaiser, C. et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73, 4481-4484 (1999).
81. Parker, G. A. et al. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13, 2541-2549 (1996).
82. Hsing, Y., Hostager, B. S. & Bishop, G. A. Characterization of CD40 signaling determinants regulating nuclear factor-κB activation in B lymphocytes. J. Immunol. 159, 4898-4906 (1997).
83. Hanissian, S. H. & Geha, R. S. JAK3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 6, 379-387 (1997).
84. Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18, 3064-3073 (1999).
85. Kieser, A. et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16, 6478-6485 (1997).
86. Ishida, T. et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271, 28745-28748 (1996).
87. Brodeur, S. R., Cheng, G., Baltimore, D. & Thorley-Lawson, D. A. Localization of the major NF-κB activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signalling motifs. J. Biol. Chem. 272, 19777-19784 (1997).
88. Izumi, K. M. & Kieff, E. D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc. Natl Acad. Sci. USA 94, 12592-12597 (1997).
89. Kieser, A., Kaiser, C. & Hammerschmidt, W. LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J. 18, 2511-2521 (1999).
90. Swart, R., Ruf, I. K., Sample, J. & Longnecker, R. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J. Virol. 74, 10838-10845 (2000).